Cancer Immunotherapies
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
21
NCT06235437
Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ASD141
Phase: Phase 1
Role: Lead Sponsor
Start: Aug 29, 2024
Completion: Dec 31, 2027
Loading map...